Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference
March 01 2021 - 4:00PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced that Executive Vice President & CFO Eli Kalif will
present at the J.P. Morgan 2021 Global High Yield and Leveraged
Finance Conference on Tuesday, March 2, 2021 at 8:30 a.m. Eastern
Time.
To access a live webcast of the presentation, visit Teva’s
Investor Relations website at
https://ir.tevapharm.com/Events-and-Presentations/events-and-presentations/default.aspx
An archived version of the presentation will be available
approximately one hour after the end of the session at the same
location.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the conference call may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, which are based on
management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our
ability to successfully compete in the marketplace; our substantial
indebtedness; our business and operations in general; compliance,
regulatory and litigation matters; other financial and economic
risks; and other factors discussed in our Annual Report on Form
10-K for the year ended December 31, 2020, including in the
sections captioned “Risk Factors” and “Forward-Looking Statements.”
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are cautioned not to put undue reliance on these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210301005838/en/
IR Contacts: United States Kevin C. Mannix (215)
591-8912 Israel Yael Ashman +972 (3) 914 8262
PR Contacts: United States Kelley Dougherty (973)
832-2810 Israel Yonatan Beker +972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Sep 2023 to Sep 2024